Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dean Wickel

Vascular Surgery Triadelphia, WV Medical Doctor

NPI 1811991763 CMS profile 263726

502 Cabela Dr, Triadelphia, WV 26059

Open in the dashboard

General payments

$29,632

225 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dean Wickel of Triadelphia, WV is reported in the CMS Open Payments database as having received $29,632 across 225 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,833 60
2024 General $5,876 36
2023 General $17,440 56
2022 General $287 15
2021 General $2,128 40
2020 General $299 7
2019 General $768 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dean Wickel
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Dean Wickel were reported at $2,833. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Dean Wickel Vascular Surgery median Middle half National median
2019 $768 $796 $226–$2,363 $163
2020 $299 $348 $118–$1,110 $114
2021 $2,128 $471 $158–$1,421 $132
2022 $287 $725 $222–$2,183 $149
2023 $17,440 $836 $257–$2,440 $160
2024 $5,876 $909 $252–$2,619 $164
2025 $2,833 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $26,244 151 payments
  2. Boston Scientific Corporation $1,401 41 payments
  3. Endologix, Inc. $499 3 payments
  4. Integra LifeSciences Corporation $491 1 payment
  5. Silk Road Medical, Inc. $339 7 payments
  6. W. L. Gore & Associates, Inc. $160 2 payments
  7. Ethicon US, LLC $89 4 payments
  8. Biotronik Inc. $79 2 payments
  9. Baxter Healthcare $58 1 payment
  10. Thrombolex, Inc. $48 2 payments
  11. Other $224 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,375 4 payments
  2. Travel and Lodging $10,873 22 payments
  3. Food and Beverage $5,855 197 payments
  4. Long term medical supply or device loan $491 1 payment
  5. Education $38 1 payment
Products named General payments · program years 2019–2025
  1. HawkOne $8,467 72 payments
  2. IN.PACT Admiral $8,148 18 payments
  3. TurboHawk $6,031 16 payments
  4. Ellipsys $1,698 12 payments
  5. MO.MA ULTRA $915 9 payments
  6. MICROMATRIX $491 1 payment
  7. Ovation $389 2 payments
  8. SilverHawk $373 3 payments
  9. ENROUTE Transcarotid Stent $309 6 payments
  10. ENROUTE Transcarotid Neuroprotection System $309 6 payments
  11. Other $3,409 97 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

319

Median for Vascular Surgery: 122

Drug cost

$47,743

Median for Vascular Surgery: $14,135

Branded share of claims

71.8%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 37 $23,839
Xarelto Rivaroxaban Brand 26 $20,922
Clopidogrel Clopidogrel Bisulfate Brand 118 $1,780
Gabapentin Generic 34 $419
Cilostazol Generic 17 $404
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 26 $154
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 22 $111
Atorvastatin Calcium Generic 14 $67
Meloxicam Generic 14 $30
Tramadol Hcl Generic 11 $15

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 124 billing codes

Paid by Medicare

$127,552

Medicare's payments for the services billed

Medicare patients

689

Average age 74

Services billed

1,364

317 women, 372 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 46%
Diabetes 44%
Heart failure 37%
Chronic kidney disease 37%
Atrial fibrillation 34%
COPD 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

225 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record